Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Archives of Neurology

• Publication date

  2005-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/ARCHNEUR.62.4.563PMID 15824253
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human Dermal Microvascular Endothelial Cells Produce Nerve Growth Factor: Implications for Wound Repair

  2003influential reference
• Characteristic gene expression profile of primary human cerebral endothelial cells

  2002influential reference
• Migration of multiple sclerosis lymphocytes through brain endothelium.

  2002cited by this paper
• Randomized controlled trial of interferon- beta-1a in secondary progressive MS

  2001cited by this paper
• Interleukin-1 beta, but not IL-1 alpha, mediates nerve growth factor secretion from rat astrocytes via type I IL-1 receptor.

  2001cited by this paper
• Final analysis of the European multicenter trial on IFNβ-1b in secondary-progressive MS

  2001cited by this paper
• Anti‐inflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration

  2001cited by this paper
• Glial cell influence on the human blood‐brain barrier

  2001cited by this paper
• Regulation of Th1 and Th2 Lymphocyte Migration by Human Adult Brain Endothelial Cells

  2001cited by this paper
• Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability.

  2001cited by this paper
• Axonal metabolic recovery in multiple sclerosis patients treated with interferon β–1b

  2001cited by this paper
• Complex immunomodulatory effects of interferon‐β in multiple sclerosis include the upregulation of T helper 1‐associated marker genes

  2001cited by this paper
• Editorial commentary to Narayanan et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b.

  2001cited by this paper
• Randomized controlled trial of interferon-beta-1a in secondary progressive MS

  2001cited by this paper
• Interleukin‐1β, but not IL‐1α, mediates nerve growth factor secretion from rat astrocytes via type I IL‐1 receptor

  2001cited by this paper
• B7 Expression and Antigen Presentation by Human Brain Endothelial Cells: Requirement for Proinflammatory Cytokines

  2000cited by this paper
• Vascular endothelial cells synthesize and secrete brain‐derived neurotrophic factor

  2000influential reference
• Surprising Pleiotropy of Nerve Growth Factor in the Treatment of Experimental Autoimmune Encephalomyelitis

  2000cited by this paper
• Human Nerve Growth Factor Protects Common Marmosets against Autoimmune Encephalomyelitis by Switching the Balance of T Helper Cell Type 1 and 2 Cytokines within the Central Nervous System

  2000cited by this paper
• A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases.

  1999cited by this paper
• Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS

  1999cited by this paper
• Axonal transection in the lesions of multiple sclerosis.

  1998cited by this paper
• Inflammatory Signals Induce Neurotrophin Expression in Human Microglial Cells

  1998cited by this paper
• A Culture Model of Reactive Astrocytes: Increased Nerve Growth Factor Synthesis and Reexpression of Cytokine Responsiveness

  1998cited by this paper
• AXONAL TRANSECTION IN THE LESIONS OF MULTIPLE SCLEROSIS

  1998cited by this paper
• Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives.

  1997cited by this paper
• Axonal damage in acute multiple sclerosis lesions.

  1997cited by this paper
• Comparison of phenotypic and functional properties of immediately ex vivo and cultured human adult microglia

  1996cited by this paper
• Differential susceptibility of human CNS-derived cell populations to TNF-dependent and independent immune-mediated injury

  1995cited by this paper
• Inflammatory cytokines in the brain: does the CNS shape immune responses?

  1994cited by this paper
• Rapid separation of CD4+ and CD19+ lymphocyte populations from human peripheral blood by a magnetic activated cell sorter (MACS).

  1993cited by this paper
• Efficient immunoselection of cytolytic effectors with a magnetic cell sorter.

  1993cited by this paper
• A critical evaluation of the magnetic cell sorter and its use in the positive and negative selection of CD45RO+ cells.

  1992cited by this paper

• Synthetic microneurotrophins: Neurotrophin receptors for therapeutics of neurodegenerative diseases

  2025cites this paper
• Stimulator of Interferon Genes (STING)-Type I Interferon Signaling: Bridging Immunity and Pain.

  2025cites this paper
• The impact of disease modifying therapies on cognitive functions typically impaired in multiple sclerosis patients: a clinician’s review

  2023cites this paper
• Nerve Growth Factor and Autoimmune Diseases

  2023cites this paper
• Analysis of β-nerve growth factor and its precursor during human pregnancy by immunoaffinity-liquid chromatography tandem mass spectrometry

  2023cites this paper
• Emerging Roles of Type-I Interferons in Neuroinflammation, Neurological Diseases, and Long-Haul COVID

  2022cites this paper
• Interferon beta attenuates recognition memory impairment and improves brain glucose uptake in a rat model of Alzheimer's disease: Involvement of mitochondrial biogenesis and PI3K pathway.

  2022cites this paper
• The role of type I IFN in autoimmune and autoinflammatory diseases with CNS involvement

  2022influential citation
• Axonal Regeneration: Underlying Molecular Mechanisms and Potential Therapeutic Targets

  2022cites this paper
• Intranasal interferon-beta as a promising alternative for the treatment of Alzheimer's disease

  2022cites this paper
• Intranasal interferon-beta alleviates anxiety and depressive-like behaviors by modulating microglia polarization in an Alzheimer's disease model.

  2022cites this paper
• Type I IFN signaling in T regulatory cells modulates chemokine production and myeloid derived suppressor cells trafficking during EAE.

  2020cites this paper
• Interferon beta ameliorates cognitive dysfunction in a rat model of Alzheimer's disease: Modulation of hippocampal neurogenesis and apoptosis as underlying mechanism.

  2019cites this paper
• Genetic Markers for Personalized Therapy of Polygenic Diseases: Pharmacogenetics of Multiple Sclerosis

  2019cites this paper
• Type I Interferons in NeuroHIV

  2019cites this paper
• Nerve Growth Factor modulates LPS ‐ induced microglial glycolysis and inflammatory responses

  2019cites this paper
• Intranasal interferon beta improves memory and modulates inflammatory responses in a mutant APP-overexpressing rat model of Alzheimer's disease.

  2019cites this paper
• Immunogenicity of biopharmaceuticals in chronic inflammatory diseases

  2018cites this paper
• Down-regulation of RORA gene expression in the blood of multiple sclerosis patients

  2018cites this paper
• Immune-cell BDNF expression in treatment-naïve relapsing-remitting multiple sclerosis patients and following one year of immunomodulation therapy.

  2018cites this paper
• Multiple Sclerosis: Basic and Clinical.

  2017cites this paper
• Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a

  2017cites this paper
• Effects of Anti-viral Acute Phase Response on Hippocampal Glutamate Regulation

  2016cites this paper
• Interferon-β Inhibits Neurotrophin 3 Signalling and Pro-Survival Activity by Upregulating the Expression of Truncated TrkC-T1 Receptor

  2016cites this paper
• Longitudinal time-domain optic coherence study of retinal nerve fiber layer in IFNβ-treated and untreated multiple sclerosis patients

  2016cites this paper
• The Inorganic Side of NGF: Copper(II) and Zinc(II) Affect the NGF Mimicking Signaling of the N-Terminus Peptides Encompassing the Recognition Domain of TrkA Receptor

  2016cites this paper
• IFN-β and multiple sclerosis: cross-talking of immune cells and integration of immunoregulatory networks.

  2015cites this paper
• Increased Serum Brain-derived Neurotrophic Factor in Multiple Sclerosis Patients on Interferon-&bgr; and Its Impact on Functional Abilities

  2015cites this paper
• Immune System Induction of Nerve Growth Factor in an Animal Model of Multiple Sclerosis: Implications in Re-Myelination and Myelin Repair.

  2015cites this paper
• A pilot study on the use of interferon beta-1a in early Alzheimer’s disease subjects

  2014cites this paper
• Adipose tissue-derived mesenchymal stem cells cultured at high cell density express brain-derived neurotrophic factor and exert neuroprotective effects in a 6-hydroxydopamine rat model of Parkinson’s disease

  2014cites this paper
• Nanoparticles for Diagnosis and/or Treatment of Alzheimer's Disease

  2014cites this paper
• Type I interferons up-regulate the expression and signalling of p75 NTR/TrkA receptor complex in differentiated human SH-SY5Y neuroblastoma cells.

  2014cites this paper
• Neue Behandlungsziele bei Multipler Sklerose: Mögliche neuroprotektive Aspekte etablierter und neuer Immuntherapeutika

  2014cites this paper
• Drug therapy for multiple sclerosis

  2014cites this paper
• Exploring the role of nerve growth factor in multiple sclerosis: implications in myelin repair.

  2014cites this paper
• The Nerve Growth Factor Signaling and Its Potential as Therapeutic Target for Glaucoma

  2014cites this paper
• New findings and old controversies in the research of multiple sclerosis and its model experimental autoimmune encephalomyelitis

  2013cites this paper
• Neuroprotektion durch Beta-Interferone

  2013cites this paper
• Effects of Current Medical Therapies on Reparative and Neuroprotective Functions in Multiple Sclerosis

  2013cites this paper
• Prediction of passive blood-brain barrier permeability with PAMPA: from small molecules to complex formulations

  2013cites this paper
• Pharmakologie von Interferon beta-1b

  2013cites this paper
• Treatment of cognitive impairment in patients with multiple sclerosis

  2012cites this paper
• What Do Effective Treatments for Multiple Sclerosis Tell Us about the Molecular Mechanisms Involved in Pathogenesis?

  2012cites this paper
• Retinal Nerve Fibre Layer Thinning in Patients with Clinically Isolated Optic Neuritis and Early Treatment with Interferon-Beta

  2012cites this paper
• Interferon–β Induces Hepatocyte Growth Factor in Monocytes of Multiple Sclerosis Patients

  2012cites this paper
• The Role of Neurotrophins in Multiple Sclerosis—Pathological and Clinical Implications

  2012cites this paper
• Cognitive deficit is related to immune-cell beta-NGF in multiple sclerosis patients.

  2012cites this paper
• Possible Effect of Immunomodulatory Treatment on the Development of Thyroid Gland Pathology in Patients with Multiple Sclerosis

  2012cites this paper
• Neuroinflammation and neuroprotection: an update on (future) neurotrophin-related strategies in multiple sclerosis treatment.

  2011cites this paper
• Interferon β-1b and glatiramer acetate effects on permanent black hole evolution

  2011cites this paper
• Targeting Progressive Neuroaxonal Injury

  2011cites this paper
• The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis

  2011cites this paper
• [Diagnosis and treatment of multiple sclerosis].

  2011cites this paper
• Evolving expectations around early management of multiple sclerosis

  2010cites this paper
• Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing—remitting multiple sclerosis

  2010cites this paper
• Interferon-β mechanisms of action in multiple sclerosis

  2010cites this paper
• Transient signaling of Erk1/2, Akt and PLCgamma induced by nerve growth factor in brain capillary endothelial cells.

  2010cites this paper
• Interferon-β treatment normalises the inhibitory effect of serum from multiple sclerosis patients on oligodendrocyte progenitor proliferation.

  2010cites this paper
• Immunomodulatory drug treatment in multiple sclerosis

  2010cites this paper
• Future neuroprotective strategies.

  2010cites this paper
• The role of natalizumab in the treatment of multiple sclerosis.

  2010cites this paper
• Bimodal effect of interferon-β on astrocyte proliferation and survival: Importance of nuclear factor-κB.

  2010cites this paper
• The blood-brain barrier in brain homeostasis and neurological diseases.

  2009cites this paper
• [Neurodegeneration and neuroprotection in multiple sclerosis].

  2009cites this paper
• Protective autoimmunity in the nervous system.

  2009cites this paper
• Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis

  2009cites this paper
• Linkage between immunomodulation, neuroprotection and neurogenesis.

  2009cites this paper
• Early stage and long term treatment of multiple sclerosis with interferon-β

  2009cites this paper
• Multiple sclerosis relapses: a multivariable analysis of residual disability determinants

  2009cites this paper
• Brain-derived neurotrophic factor and TrkB receptor in experimental autoimmune encephalomyelitis and multiple sclerosis.

  2009cites this paper
• The role of neurotrophic factors in the pathology and treatment of multiple sclerosis

  2009influential citation
• Interferon-beta protects astrocytes against tumour necrosis factor-induced apoptosis via activation of p38 mitogen-activated protein kinase.

  2008cites this paper
• of the clinical evidence for interferon β 1 a ( Rebif ® ) in the treatment of multiple sclerosis

  2008cites this paper
• Macrophages, Microglia, and Dendritic C

  2008cites this paper
• Central nervous system effects of current and emerging multiple sclerosis-directed immuno-therapies.

  2008cites this paper
• Review of the clinical evidence for interferon β 1a (Rebif®) in the treatment of multiple sclerosis

  2008cites this paper
• Death receptor expression and function at the human blood brain barrier.

  2007cites this paper
• Neurodegeneration and -protection in autoimmune CNS inflammation.

  2007cites this paper
• Interferon-β treatment for multiple sclerosis

  2007cites this paper
• New natural history of interferon-beta-treated relapsing multiple sclerosis.

  2007cites this paper
• The effect of interferon-β on black holes in patients with multiple sclerosis

  2007cites this paper
• New natural history of interferon‐β–treated relapsing multiple sclerosis

  2007cites this paper
• Review article Neurodegeneration and -protection in autoimmune CNS inflammation

  2007cites this paper
• The effect of interferon-beta on black holes in patients with multiple sclerosis.

  2007cites this paper
• Interferon-beta treatment for multiple sclerosis.

  2007cites this paper
• Interferon Beta-1b May Reverse Axonal Dysfunction in Multiple Sclerosis

  2007cites this paper
• Interferon-beta is neuroprotective against the toxicity induced by activated microglia.

  2007cites this paper
• Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor.

  2007cites this paper
• Von der Neuroinflammation zur Neurodegeneration

  2006cites this paper
• The measurement and clinical relevance of brain atrophy in multiple sclerosis.

  2006cites this paper
• Neuroprotection in multiple sclerosis.

  2006cites this paper
• Effects of interferon-beta-1a on neuronal survival under autoimmune inflammatory conditions.

  2006cites this paper
• [Neuroprotective effect of the long-term beta-interferon course in multiple sclerosis: direct and indirect mechanisms].

  2006cites this paper
• Statins reduce human blood–brain barrier permeability and restrict leukocyte migration: Relevance to multiple sclerosis

  2006cites this paper
• Effects of glatiramer acetate and interferon-beta on neurodegeneration in a model of multiple sclerosis: a comparative study.

  2006cites this paper
• Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy.

  2006influential citation
• Immune Functions of Brain Endothelial Cells

  2005cites this paper